2025-04-30 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Review

**0. Key Figures Summary:**

* **RXRX Cumulative Return:** -47.69%
* **VOO (S&P 500) Cumulative Return:** 17.77%
* **RXRX vs. VOO Return Difference:** -65.5% (Relative Rank: 7.5th percentile)
* **Current Closing Price:** $5.72
* **Market Risk Indicator (MRI):** 0.379 (Medium Risk)


**1. Performance Comparison & Company Overview:**

Recursion Pharmaceuticals Inc. (RXRX) is a biotechnology company leveraging AI-driven drug discovery.  Comparing RXRX's cumulative return of -47.69% to the S&P 500's 17.77% reveals a significant underperformance.  The -65.5% difference places RXRX in the 7.5th percentile of its historical performance relative to the S&P 500, indicating consistent underperformance.

**Alpha and Beta Analysis:**

The provided data shows consistently negative alpha and high beta across the analyzed periods (2021-2025).  This suggests RXRX's performance is highly correlated with the market (high beta) but significantly underperforms the market (negative alpha). The market cap fluctuated between $2.3B and $4B during this period.  The high MDD (Maximum Drawdown) consistently around 73.6% further highlights the significant risk associated with this investment.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -12.0% | 4.0 |
| 2022-2024  | 0.0% | 73.6% | -22.0% | 2.8 |
| 2023-2025  | 4.0% | 73.6% | -13.0% | 2.3 |


**2. Recent Price Movement:**

* **Closing Price:** $5.72
* **Previous Close:** $5.84
* **Daily Change:** -2.05%
* **5-Day Moving Average:** $5.72
* **20-Day Moving Average:** $5.21
* **60-Day Moving Average:** $6.65

The price is currently below all three moving averages, suggesting a potential downtrend. The recent daily drop of -2.05% contributes to this bearish signal.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.379 (Medium Risk) indicating moderate market volatility.
* **RSI:** 73.46 (Approaching overbought territory, suggesting potential short-term correction)
* **PPO:** 2.55 (Positive, suggesting bullish momentum but needs to be considered in context with other indicators)
* **20-Day Relative Strength Change:** -4.8% (Short-term bearish signal)
* **Expected Return:** -450.5% (This extremely negative figure suggests a very pessimistic outlook on future returns relative to the S&P 500 over a 2+ year time horizon).  This requires further investigation as it's an exceptionally low estimate.

The -2.05% daily change in price, while not dramatic, confirms a minor downward movement and contributes to the overall negative picture.


**4. Recent Earnings Analysis:**

The company has consistently reported negative EPS and low revenue figures.  There's no clear trend of improvement.

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2024-11-06 | -0.34 | $0.03 B      |
| 2024-08-08 | -0.40 | $0.01 B      |
| 2024-05-09 | -0.39 | $0.01 B      |
| 2023-11-09 | -0.43 | $0.01 B      |
| 2024-11-06 | -0.43 | $0.01 B      |


**5. Financial Information:**

The financial statements show significant issues with profitability.  While revenue increased in Q3 2024, profit margins remain erratic and largely negative.  Equity has fluctuated, and ROE is consistently negative, indicating the company is not generating returns on its equity.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.00B | -183.62% |
| 2024-09-30 | $0.03B | 53.69% |
| 2024-06-30 | $0.01B | 36.14% |
| 2024-03-31 | $0.01B | 17.23% |
| 2023-12-31 | $0.01B | 6.99% |


**Capital and Profitability:**

| Quarter | Equity | ROE     |
|---------|---------|---------|
| 2024-12-31 | $1.03B | -17.29% |
| 2024-09-30 | $0.52B | -18.27% |
| 2024-06-30 | $0.58B | -16.69% |
| 2024-03-31 | $0.40B | -22.78% |
| 2023-12-31 | $0.46B | -20.07% |


**6. Overall Analysis:**

RXRX exhibits significant underperformance relative to the S&P 500, supported by consistently negative alpha, high beta, high maximum drawdown, and negative expected returns.  The company's financials reveal consistent losses and fluctuating profitability. While the recent increase in revenue in Q3 2024 offers a sliver of hope, the overall picture remains very bearish.  The negative expected return of -450.5% warrants further investigation to ensure the accuracy of this calculation.  Further research into the company's pipeline and future prospects is crucial before making any investment decisions.  Given the current data, a long-term investment in RXRX carries substantial risk.
